title: Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience.
abstract: BACKGROUND
  Triple-negative breast cancer (TNBC) lacks estrogen and progesterone receptors and does not overexpress HER2. It displays a distinct clinical behavior. This study aims to assess the clinical, molecular and prognostic characteristics of TNBC patients.
  
  
  METHODS
  TNBC patients, referred to a tertiary medical center, 1/1/2000 - 31/12/2005, were included. Clinical, molecular and prognostic characteristics were retrospectively collected from patients' records.
  
  
  RESULTS
  Overall, 122 consecutive TNBC patients were included with a median age of 54 years. Among the TNBC patients, 101 (82.8%) were Jews and 21 (17.2%) were Arabs. Family history for breast cancer was reported in 30 patients (24.6%). Genetic counseling was conducted in 30 patients (24.6%); 22/30 (73.3%) had BRCA1/2 mutations. Median tumor size was 2 cm and positive lymph nodes were detected in pathological examination in 40 patients (34%). At the time of data analysis, 21/118 patients (17.8%), who initially presented with early disease, had developed metastasis. Local recurrence was detected in four patients (3.4%). The overall survival (OS) was significantly longer for patients younger than 60 years compared to those ≥ 60 years, (Hazard ratio (HR) =2.1, p=0.046). Nulliparous patients had significantly higher OS than patients with a reproductive history of ≥ 4 children. (HR=0.31, p= 0.041). Mortality rate was higher for Arabs versus Jews but did not reach significance, (HR=1.33; P=0.64).
  
  
  CONCLUSIONS
  TNBC represents an exclusive clinical behavior. Older age and parity were found to be poor prognostic factors. Further larger studies are needed to reaffirm our findings and explore the genetics among non-BRCA1/2 TNBC patients.
authors.affiliation: Division of Oncology, Rambam Health Care Campus, HaAliya Street 8, Haifa, 35254 Israel ; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa, 31096 Israel.
authors.forename: Karama
authors.initials: K
authors.lastname: Asleh-Aburaya
authors.affiliation: Division of Oncology, Rambam Health Care Campus, HaAliya Street 8, Haifa, 35254 Israel ; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa, 31096 Israel.
authors.forename: Georgeta
authors.initials: G
authors.lastname: Fried
keywords: BRCA mutation; Distant metastasis; Overall Survival; Triple Negative Breast Cancer
references.citation: Breast Cancer Res Treat. 2011 Aug;129(1):185-90
references.pmid: 21394499
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4515-21
references.pmid: 19704069
references.citation: N Engl J Med. 2010 Nov 11;363(20):1938-48
references.pmid: 21067385
references.citation: Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12
references.pmid: 23012306
references.citation: J Natl Cancer Inst. 2011 Mar 16;103(6):470-7
references.pmid: 21346227
references.citation: Eur J Cancer. 2000 May;36(8):983-6
references.pmid: 10885601
references.citation: CA Cancer J Clin. 2011 Nov-Dec;61(6):409-18
references.pmid: 21969133
references.citation: J Clin Oncol. 2008 Sep 10;26(26):4282-8
references.pmid: 18779615
references.citation: Breast Cancer Res. 2013;15(5):R98
references.pmid: 24148581
references.citation: Mod Pathol. 2011 Feb;24(2):157-67
references.pmid: 21076464
references.citation: Breast Cancer Res. 2010;12(6):R99
references.pmid: 21092082
references.citation: N Engl J Med. 2007 Jul 12;357(2):115-23
references.pmid: 17625123
references.citation: J Med Genet. 2011 Aug;48(8):520-2
references.pmid: 21653198
references.citation: Radiol Oncol. 2011 Mar;45(1):46-52
references.pmid: 22933934
references.citation: Breast Cancer Res. 2009;11(2):R18
references.pmid: 19320967
references.citation: Breast. 2007 Jun;16(3):280-92
references.pmid: 17257844
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1480-90
references.pmid: 11896095
references.citation: Mod Pathol. 2010 Jan;23(1):123-33
references.pmid: 19855377
references.citation: Nat Rev Clin Oncol. 2010 Dec;7(12):683-92
references.pmid: 20877296
references.citation: Breast Cancer Res Treat. 2013 Apr;138(3):941-50
references.pmid: 23553566
references.citation: Cancer. 2011 Jun 15;117(12):2747-53
references.pmid: 21656753
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1082-9
references.pmid: 21233401
references.citation: Cancer. 2011 Jul 15;117(14):3093-100
references.pmid: 21264845
references.citation: Ann Surg Oncol. 2013 Oct;20(10):3254-8
references.pmid: 23975317
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4214-20
references.pmid: 20733129
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
references.pmid: 17671126
references.citation: Cancers (Basel). 2010 May 28;2(2):1040-65
references.pmid: 24281106
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2784-95
references.pmid: 20404251